Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.57 |
| ▸ | PDE5A | O76074 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2663026 | 0.94 | PDE5A (0.52) | HSP90AA1PDE5ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL14172936 | 0.91 | PDE5A (0.59) | HSP90AA1PDE5ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL13330092 | 0.89 | CYP1A2 (0.57) | HSP90AA1PDE5ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL4441944 | 0.84 | MAPT (0.61) | HSP90AA1CYP1A2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL11410724 | 0.84 | SMN1; SMN2 (0.61) | PDE5ACYP1A2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL20349597 | 0.84 | SMN1; SMN2 (0.51) | HSP90AA1PDE5ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL5009820 | 0.83 | MAPT (0.62) | HSP90AA1CYP1A2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL3645530 | 0.83 | SMN1; SMN2 (0.77) | SMN1; SMN2ALDH1A1HPGDNPC1MAPT | |
| SCHEMBL6313513 | 0.82 | CYP3A4 (0.55) | HSP90AA1PDE5ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL15400405 | 0.81 | CYP3A4 (0.68) | HSP90AA1CYP1A2CYP3A4CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580822-B2 | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | REVIVA PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580822-B2 | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | REVIVA PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580822-B2 | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | REVIVA PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120252842-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE BASED CHOLINESTERASE INHIBITORS | REVIVA PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120252842-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE BASED CHOLINESTERASE INHIBITORS | REVIVA PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120252842-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE BASED CHOLINESTERASE INHIBITORS | REVIVA PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-8247563-B2 | 5,6-dimethoxy-2-(piperidin-4-ylmethyl)-2,3-dihydro-1H-inden-1-one ; for therapy of Alzheimer's disease, myasthenia gravis, Huntingtons disease or glaucoma | REVIVA PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247563-B2 | 5,6-dimethoxy-2-(piperidin-4-ylmethyl)-2,3-dihydro-1H-inden-1-one ; for therapy of Alzheimer's disease, myasthenia gravis, Huntingtons disease or glaucoma | REVIVA PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247563-B2 | 5,6-dimethoxy-2-(piperidin-4-ylmethyl)-2,3-dihydro-1H-inden-1-one ; for therapy of Alzheimer's disease, myasthenia gravis, Huntingtons disease or glaucoma | REVIVA PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| CN-101626688-A | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | REVIVA PHARMACEUTICALS INC | 2010-01-13 | — | — | CN | disclosed |
| EP-2114166-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE BASED CHOLINESTERASE INHIBITORS | Reviva Pharmaceuticals, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20080153878-A1 | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | REVIVA PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| WO-2008073452-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE BASED CHOLINESTERASE INHIBITORS | REVIVA PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153878-A1 | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | ACHE, BCHE, CHKA | HSP90AA1 4085/4885PDE5A 611/4885CYP1A2 65/4885 |
| US-20120252842-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE BASED CHOLINESTERASE INHIBITORS | ACHE, BCHE, CHKA | HSP90AA1 4085/4885PDE5A 611/4885CYP1A2 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.